
<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): December 20, 2004



                          ENCYSIVE PHARMACEUTICALS INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)



         DELAWARE                     0-20117                    13-3532643
- --------------------------------------------------------------------------------
(State or other jurisdiction        (Commission                (IRS Employer
     of incorporation)              File Number)            Identification No.)



   6700 WEST LOOP, 4TH FLOOR, BELLAIRE, TEXAS                  77401
    (Address of principal executive offices)                 (Zip Code)


        Registrant's telephone number, including area code: 713-796-8822



                                 Not Applicable
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))



<PAGE>


ITEM 8.01 OTHER EVENTS.

         Encysive Pharmaceuticals (Nasdaq: ENCY) today announced top line
results from STRIDE-4, a Phase III, randomized, double-blind, placebo-controlled
safety and efficacy study of Thelin(TM) treatment in patients with pulmonary
arterial hypertension (PAH).

         The full text of the press release is furnished herewith as Exhibit
99.1 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

              (c) Exhibits.

                  99.1     Press Release.








                            [SIGNATURE PAGE FOLLOWS]



<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                            ENCYSIVE PHARMACEUTICALS INC.
                                                    (Registrant)

Date:  December 20, 2004
                                               /s/ Stephen L. Mueller
                                      ------------------------------------------
                                                 Stephen L. Mueller
                                      Vice President, Finance and Administration
                                              Secretary and Treasurer





